Jazz Pharmaceuticals plc Revenue
Jazz Pharmaceuticals plc (JAZZ) reported Revenue of $1.21 billion for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-03
- Jazz Pharmaceuticals plc revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $1.21B, a 15.55% increase year-over-year.
- Jazz Pharmaceuticals plc revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $1.07B, a 19.06% increase year-over-year.
- Jazz Pharmaceuticals plc revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $1.20B, a 10.09% increase year-over-year.
- Jazz Pharmaceuticals plc revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $1.13B, a 6.74% increase year-over-year.
- Jazz Pharmaceuticals plc revenue from contract with customer, excluding assessed tax for fiscal 2025 was $4.27B, a 4.88% increase from fiscal 2024.
- Jazz Pharmaceuticals plc revenue from contract with customer, excluding assessed tax for fiscal 2024 was $4.07B, a 6.12% increase from fiscal 2023.
- Jazz Pharmaceuticals plc revenue from contract with customer, excluding assessed tax for fiscal 2023 was $3.83B, a 4.78% increase from fiscal 2022.
- Jazz Pharmaceuticals plc revenue from contract with customer, excluding assessed tax for fiscal 2022 was $3.66B, a 18.26% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 3 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1.21B 10-Q · filed 2026-08-03 | $2.28B 10-Q · filed 2026-08-03 | $3.48B derived: sum of 3 quarters · filed 2026-08-03 | $4.60B derived: sum of 4 quarters · filed 2026-08-03 | ||
| 2026-03-31 | $1.07B 10-Q · filed 2026-05-05 | $2.27B derived: sum of 2 quarters · filed 2026-05-05 | $3.39B derived: sum of 3 quarters · filed 2026-05-05 | $4.44B derived: sum of 4 quarters · filed 2026-08-03 | ||
| 2025-12-31 | $1.20B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $2.32B derived: sum of 2 quarters · filed 2026-02-24 | $3.37B derived: sum of 3 quarters · filed 2026-08-03 | $4.27B 10-K · filed 2026-02-24 | ||
| 2025-09-30 | $1.13B 10-Q · filed 2025-11-05 | $2.17B derived: sum of 2 quarters · filed 2026-08-03 | $3.07B 10-Q · filed 2025-11-05 | $4.16B derived: sum of 4 quarters · filed 2026-08-03 | ||
| 2025-06-30 | $1.05B 10-Q · filed 2026-08-03 | $1.05B 10-Q · filed 2025-08-06 | $1.94B 10-Q · filed 2026-08-03 | $1.94B 10-Q · filed 2025-08-06 | $3.03B derived: sum of 3 quarters · filed 2026-08-03 | $4.09B derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $897.80M 10-Q · filed 2026-05-05 | $897.84M 10-Q · filed 2025-05-07 | $1.99B derived: sum of 2 quarters · filed 2026-05-05 | $3.04B derived: sum of 3 quarters · filed 2026-05-05 | $4.06B derived: sum of 4 quarters · filed 2026-05-05 | |
| 2024-12-31 | $1.09B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $2.14B derived: sum of 2 quarters · filed 2026-02-24 | $3.17B derived: sum of 3 quarters · filed 2026-02-24 | $4.07B 10-K · filed 2026-02-24 | ||
| 2024-09-30 | $1.05B 10-Q · filed 2025-11-05 | $2.08B derived: sum of 2 quarters · filed 2025-11-05 | $2.98B 10-Q · filed 2025-11-05 | $3.99B derived: sum of 4 quarters · filed 2026-02-24 | ||
| 2024-06-30 | $1.02B 10-Q · filed 2025-08-06 | $1.93B 10-Q · filed 2025-08-06 | $2.94B derived: sum of 3 quarters · filed 2026-02-24 | $3.91B derived: sum of 4 quarters · filed 2026-02-24 | ||
| 2024-03-31 | $901.98M 10-Q · filed 2025-05-07 | $1.91B derived: sum of 2 quarters · filed 2026-02-24 | $2.89B derived: sum of 3 quarters · filed 2026-02-24 | $3.84B derived: sum of 4 quarters · filed 2026-02-24 | ||
| 2023-12-31 | $1.01B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $1.98B derived: sum of 2 quarters · filed 2026-02-24 | $2.94B derived: sum of 3 quarters · filed 2026-02-24 | $3.83B 10-K · filed 2026-02-24 | ||
| 2023-09-30 | $972.14M 10-Q · filed 2024-11-07 | $1.93B derived: sum of 2 quarters · filed 2024-11-07 | $2.82B 10-Q · filed 2024-11-07 | $3.79B derived: sum of 4 quarters · filed 2025-02-26 | ||
| 2023-06-30 | $957.32M 10-Q · filed 2024-08-01 | $1.85B 10-Q · filed 2024-08-01 | $2.82B derived: sum of 3 quarters · filed 2025-02-26 | $3.76B derived: sum of 4 quarters · filed 2025-02-26 | ||
| 2023-03-31 | $892.81M 10-Q · filed 2024-05-02 | $1.86B derived: sum of 2 quarters · filed 2025-02-26 | $2.81B derived: sum of 3 quarters · filed 2025-02-26 | $3.74B derived: sum of 4 quarters · filed 2025-02-26 | ||
| 2022-12-31 | $972.12M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $1.91B derived: sum of 2 quarters · filed 2025-02-26 | $2.85B derived: sum of 3 quarters · filed 2025-02-26 | $3.66B 10-K · filed 2025-02-26 | ||
| 2022-09-30 | $940.65M 10-Q · filed 2023-11-08 | $1.87B derived: sum of 2 quarters · filed 2023-11-08 | $2.69B 10-Q · filed 2023-11-08 | $3.58B derived: sum of 4 quarters · filed 2024-02-28 | ||
| 2022-06-30 | $932.88M 10-Q · filed 2023-08-09 | $1.75B 10-Q · filed 2023-08-09 | $2.64B derived: sum of 3 quarters · filed 2024-02-28 | $3.48B derived: sum of 4 quarters · filed 2024-02-28 | ||
| 2022-03-31 | $813.72M 10-Q · filed 2023-05-10 | $1.71B derived: sum of 2 quarters · filed 2024-02-28 | $2.55B derived: sum of 3 quarters · filed 2024-02-28 | $3.30B derived: sum of 4 quarters · filed 2024-02-28 | ||
| 2021-12-31 | $896.73M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $1.73B derived: sum of 2 quarters · filed 2024-02-28 | $2.49B derived: sum of 3 quarters · filed 2024-02-28 | $3.09B 10-K · filed 2024-02-28 | ||
| 2021-09-30 | $838.12M 10-Q · filed 2022-11-09 | $1.59B derived: sum of 2 quarters · filed 2022-11-09 | $2.20B 10-Q · filed 2022-11-09 | $2.86B derived: sum of 4 quarters · filed 2022-11-09 | ||
| 2021-06-30 | $751.81M 10-Q · filed 2022-08-03 | $1.36B 10-Q · filed 2022-08-03 | $2.02B derived: sum of 3 quarters · filed 2022-08-03 | $2.63B derived: sum of 4 quarters · filed 2022-08-03 | ||
| 2021-03-31 | $607.58M 10-Q · filed 2022-05-04 | $1.27B derived: sum of 2 quarters · filed 2022-05-04 | $1.87B derived: sum of 3 quarters · filed 2022-05-04 | $2.44B derived: sum of 4 quarters · filed 2022-05-04 | ||
| 2020-12-31 | $665.52M 10-K · filed 2021-02-23 | $1.27B derived: sum of 2 quarters · filed 2021-11-09 | $1.83B derived: sum of 3 quarters · filed 2021-11-09 | $2.36B 10-K · filed 2023-03-01 | ||
| 2020-09-30 | $600.89M 10-Q · filed 2021-11-09 | $1.16B derived: sum of 2 quarters · filed 2021-11-09 | $1.70B 10-Q · filed 2021-11-09 | $2.28B derived: sum of 4 quarters · filed 2021-11-09 | ||
| 2020-06-30 | $562.44M 10-Q · filed 2021-08-03 | $1.10B 10-Q · filed 2021-08-03 | $1.68B derived: sum of 3 quarters · filed 2021-08-03 | $2.22B derived: sum of 4 quarters · filed 2021-08-03 | ||
| 2020-03-31 | $534.73M 10-Q · filed 2021-05-04 | $1.12B derived: sum of 2 quarters · filed 2021-05-04 | $1.65B derived: sum of 3 quarters · filed 2021-05-04 | $2.19B derived: sum of 4 quarters · filed 2021-05-04 | ||
| 2019-12-31 | $581.74M 10-K · filed 2021-02-23 | $1.12B derived: sum of 2 quarters · filed 2021-02-23 | $1.65B derived: sum of 3 quarters · filed 2021-02-23 | $2.16B 10-K · filed 2022-03-01 | ||
| 2019-09-30 | $537.70M 10-K · filed 2021-02-23 | $1.07B derived: sum of 2 quarters · filed 2021-02-23 | $1.58B 10-Q · filed 2020-11-02 | $2.06B derived: sum of 4 quarters · filed 2021-02-23 | ||
| 2019-06-30 | $534.13M 10-K · filed 2021-02-23 | $1.04B 10-Q · filed 2020-08-04 | $1.52B derived: sum of 3 quarters · filed 2021-02-23 | $1.99B derived: sum of 4 quarters · filed 2021-02-23 | ||
| 2019-03-31 | $508.19M 10-K · filed 2021-02-23 | $984.64M derived: sum of 2 quarters · filed 2021-02-23 | $1.45B derived: sum of 3 quarters · filed 2021-02-23 | $1.95B derived: sum of 4 quarters · filed 2021-02-23 | ||
| 2018-12-31 | $476.46M 10-K · filed 2020-02-25 | $945.83M derived: sum of 2 quarters · filed 2020-02-25 | $1.45B derived: sum of 3 quarters · filed 2020-02-25 | $1.89B 10-K · filed 2021-02-23 | ||
| 2018-09-30 | $469.37M 10-K · filed 2020-02-25 | $969.85M derived: sum of 2 quarters · filed 2020-02-25 | $1.41B 10-Q · filed 2019-11-05 | $1.85B derived: sum of 4 quarters · filed 2020-02-25 | ||
| 2018-06-30 | $500.48M 10-K · filed 2020-02-25 | $945.09M 10-Q · filed 2019-08-06 | $1.38B derived: sum of 3 quarters · filed 2020-02-25 | $1.79B derived: sum of 4 quarters · filed 2020-02-25 | ||
| 2018-03-31 | $444.61M 10-K · filed 2020-02-25 | $881.01M derived: sum of 2 quarters · filed 2020-02-25 | $1.29B derived: sum of 3 quarters · filed 2020-02-25 | $1.69B derived: sum of 4 quarters · filed 2020-02-25 | ||
| 2017-12-31 | $436.40M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $848.25M derived: sum of 2 quarters · filed 2020-02-25 | $1.24B derived: sum of 3 quarters · filed 2020-02-25 | $1.62B 10-K · filed 2020-02-25 | ||
| 2017-09-30 | $411.86M 10-Q · filed 2018-11-06 | $806.24M derived: sum of 2 quarters · filed 2018-11-06 | $1.18B 10-Q · filed 2018-11-06 | |||
| 2017-06-30 | $394.39M 10-Q · filed 2018-08-07 | $770.44M 10-Q · filed 2018-08-07 | ||||
| 2017-03-31 | $376.05M 10-Q · filed 2018-05-08 | |||||
| 2016-12-31 | $1.49B 10-K · filed 2019-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |